Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism

Journal of Clinical Investigation

Volumn 120, Issue 4, 2010, Pages 1355-1361

  McClelland, Erin E ^a   Nicola, André M ^b,c   Prados Rosales, Rafael ^b   Casadevall, Arturo ^b  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M;

ARTICLE; CELL LYSATE; CELL WALL; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOWN REGULATION; DRUG SENSITIVITY; FATTY ACID SYNTHESIS; FUNGAL METABOLISM; GENE EXPRESSION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; UPREGULATION;

AMPHOTERICIN B; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; BACTERIAL CAPSULES; CRYPTOCOCCUS NEOFORMANS; GENE EXPRESSION REGULATION, FUNGAL; LIPID METABOLISM;

EID: 77951173734     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38322     Document Type: Article

References (39)

1. Connolly SE, Thanassi DG, Benach JL. Generation of a complement- independent bactericidal IgM against a relapsing fever Borrelia. J Immunol. 2004;172(2):1191-1197.
2. Alviano DS, et al. Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes. Infect Immun. 2004;72(1):229-237.
3. Rosas AL, Nosanchuk JD, Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun. 2001;69(5):3410-3412.
4. Rodrigues ML, et al. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun. 2000;68(12):7049-7060.
5. Matthews RC, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003;47(7):2208-2216.
6. Pachl J, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42(10):1404-1413.
7. MacGill TC, MacGill RS, Casadevall A, Kozel TR. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol. 2000;164(9):4835-4842.
8. Martinez LR, Moussai D, Casadevall A. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun. 2004;72(6):3674-3679. (Pubitemid 38697802)
9. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun. 2005;73(10):6350-6362.
10. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med. 1995;181(1):405-409.
11. Larsen RA, et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother. 2005;49(3):952-958.
12. Mukherjee J, Scharff MD, Casadevall A. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun. 1995;63(9):3353-3359.
13. Crotzer VL, Mabardy AS, Weiss A, Brodsky FM. T cell receptor engagement leads to phosphorylation of clathrin heavy chain during receptor internalization. J Exp Med. 2004;199(7):981-991.
14. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991;142(2):257-265.
15. Casadevall A, Pirofski LA. New concepts in antibody-mediated immunity. Infect Immun. 2004;72(11):6191-6196.
16. Bryan RA, Zaragoza O, Zhang T, Ortiz G, Casadevall A, Dadachova E. Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell. 2005;4(2):465-475.
17. Rakesh V, et al. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans. J Phys Chem B. 2008;112(29):8514-8522.
18. Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med. 1997;185(4):685-694.
19. Kim TW, et al. Brassinosteroid signal transduction from cell-surface receptor kinases to nuclear transcription factors. Nat Cell Biol. 2009;11(10):1254-1260.
20. Park SJ, et al. Oxidative stress induces lipid-raft-mediated activation of Src homology 2 domain-containing protein-tyrosine phosphatase 2 in astrocytes. Free Radic Biol Med. 2009;46(12):1694-1702.
21. Martinez LR, Christaki E, Casadevall A. Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. J Infect Dis. 2006;194(2):261-266.
22. Zaragoza O, Casadevall A. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell Microbiol. 2006;8(12):1862-1876.
23. Pieroni JP, Harry A, Chen J, Jacobowitz O, Magnusson RP, Iyengar R. Distinct characteristics of the basal activities of adenylyl cyclases 2 and 6. J Biol Chem. 1995;270(36):21368-21373.
24. Toda T, et al. Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica. 2009;39(4):323-334.
25. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother. 1994;38(3):580-587.
26. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis. 1991;163(5):1114-1120.
27. Rodrigues ML, et al. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell. 2007;6(1):48-59.
28. Rodrigues ML, et al. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell. 2008;7(1):58-67.
29. Oliveira DL, et al. Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan. Fungal Genet Biol. 2009;46(12):956-963.
30. Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol. 2007;18(4):1239-1245.
31. Nieva J, Wentworth P Jr. The antibody-catalyzed water oxidation pathway--a new chemical arm to immune defense? Trends Biochem Sci. 2004;29(5):274-278.
32. Magliani W, Conti S, Cunha RL, Travassos LR, Polonelli L. Antibodies as crypts of antiinfective and antitumor peptides. Curr Med Chem. 2009;16(18):2305-2323.
33. Lewis RA, Hultquist DE, Baker BL, Falls HF, Gershowitz H, Penner JA. Hypercupremia associated with a monoclonal immunoglobulin. J Lab Clin Med. 1976;88(3):375-388.
34. Macura N, Zhang T, Casadevall A. Dependence of macrophage phagocytic efficacy on antibody concentration. Infect Immun. 2007;75(4):1904-1915.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
36. Maxson ME, Dadachova E, Casadevall A, Zaragoza O. Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell. 2007;6(1):95-109.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
38. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
39. Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT. Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot Cell. 2006;5(3):488-498.